

cury compounds. Such investigations are in progress in this laboratory.

Additionally, we have found that the cleavage by mercuric bromide of dialkylmercury compounds, which are free of possible complicating stereochemical features, occurs with retention of configuration. In contrast, the reduction of *sec*-butylmercuric bromide by sodium stannite to yield di-*sec*-butylmercury occurs with racemization of both R-groups.

The resolution was accomplished through the *sec*-butylmercuric mandelates. The (–)-*sec*-butylmercuric mandelate was recrystallized to constant optical rotation using dioxane as solvent, and then converted to (–)-*sec*-butylmercuric bromide by reaction with sodium bromide. The rotation of (–)-*sec*-butylmercuric bromide thus obtained is  $[\alpha]^{22D} - 25.8^\circ$  (*C* 5, ethanol),  $[\alpha]^{22D} - 25.9^\circ$  (*C* 3, acetone) (lit.<sup>2</sup>  $[\alpha]^{20D} - 24.0^\circ$  (*C* ~5, acetone)).

The cleavage of active *sec*-butylmercuric bromide by bromine to form 2-bromobutane has been studied under various conditions, and the results are similar to those obtained with the *cis*- and *trans*-4-methylcyclohexylmercuric bromides.<sup>4</sup> Depending upon reaction conditions, active or inactive *sec*-butyl bromide is obtained. In pyridine as the solvent, (+)-*sec*-butylmercuric bromide,  $[\alpha]^{22D} + 3.76^\circ$ , was treated with bromine to yield D-(+)-2-bromobutane,  $[\alpha]^{22D} + 4.15^\circ$ . Since this reaction has been shown to proceed with retention of configuration,<sup>4</sup> the configurational assignment is D-(+)-*sec*-butylmercuric bromide. The rotation of optically pure D-(+)-2-bromobutane is  $[\alpha]^{25D} + 28.6^\circ$ .<sup>5</sup> Assuming the bromine cleavage in pyridine is completely stereospecific, the empirically calculated rotation for optically pure D-(+)-*sec*-butylmercuric bromide is  $[\alpha]^{22D} - 25.9^\circ$ , which value is identical with the experimental value reported here. This appears to be the most reliable stereospecific method for making active secondary bromides.<sup>5,6</sup>

Using compounds which have more than one asymmetric center<sup>7</sup> and neighboring methoxy group,<sup>8</sup> the cleavage of dialkylmercury compounds by mercuric halides has been reported to occur, respectively, with racemization and with retention of configuration. With simple aliphatic compounds we have found the reaction occurs with retention of configuration. *sec*-Butylmagnesium bromide was added to (–)-*sec*-butylmercuric bromide,  $[\alpha]^{22D} - 6.49^\circ$ , to give (–)-*sec*-butyl-(±)-*sec*-butylmercury,  $[\alpha]^{22D} - 5.52^\circ$ . The dialkyl compound with mercuric bromide gave (–)-*sec*-butylmercuric bromide (91%),  $[\alpha]^{22D} - 3.36^\circ$ . (The rotation of the final product was approximately one-half that of the starting material.)

The stereochemistry of the reduction of 2-methoxycyclohexylmercuric iodide by sodium stannite to yield di-2-methoxycyclohexylmercury has been studied by Traylor and Winstein.<sup>9</sup> Their suggested mechanism implied that only one alkyl

group loses its configuration in the course of the reaction. We have found that with *sec*-butylmercuric bromide, both of the alkyl groups are predominantly racemized. The product (di-*sec*-butylmercury) is optically stable to the reaction conditions. (+)-*sec*-Butylmercuric bromide,  $[\alpha]^{22D} + 5.4^\circ$ , was treated with sodium stannite solution to give (+)-di-*sec*-butylmercury,  $[\alpha]^{22D} + 0.22^\circ$ , in 87% yield. Cleavage of this compound with mercuric bromide gave (+)-*sec*-butylmercuric bromide,  $[\alpha]^{22D} + 0.23^\circ$ .

(9) T. G. Traylor and S. Winstein, *J. Org. Chem.*, **23**, 1796 (1958).

DEPARTMENT OF CHEMISTRY  
UNIVERSITY OF CALIFORNIA  
BERKELEY 4, CALIFORNIA

FREDERICK R. JENSEN  
LORIS D. WHIPPLE  
DONALD K. WEDEGAERTNER  
JOHN A. LANDGREBE

RECEIVED DECEMBER 22, 1958


#### COENZYME Q. VI. ETHOXY HOMOLOGS OF COENZYME Q<sub>10</sub>. ARTIFACT OF ISOLATION

Sir:

We have characterized ethoxy homologs of coenzyme Q<sub>10</sub>; an artifact of isolation is evident. Ubiquinone<sup>1,2,3</sup> and these ethoxy homologs are very similar and differ from coenzyme Q<sub>10</sub>.

Our isolation of coenzyme Q<sub>10</sub> has been described,<sup>4</sup> and we initially observed no evidence for the presence of related quinones. Continued processing yielded lower melting material. Further purification separated coenzyme Q<sub>10</sub> from another quinone, m.p. 43–43.5°. *Anal.* Found: C, 82.19; H, 10.34.

Ultraviolet, infrared and nuclear magnetic resonance spectra agree with formula I for this quinone; n.m.r. data were particularly revealing. The n.m.r. spectrum of CH<sub>3</sub>CH<sub>2</sub>O— was observed as



two members of the methyl triplet at –144 and –136.5 c.p.s. and three members of the –CH<sub>2</sub>O– quartet at –29, –22, and –14.5 c.p.s., the missing members being obscured by the large CH<sub>3</sub>– and CH<sub>3</sub>O– resonances of the rest of the molecule.

Our isolation included a step using hot ethanolic alkali. It was thought that an alcohol exchange reaction had occurred. When pure coenzyme Q<sub>10</sub> was subjected to this isolation step in a simulated process, the ethoxy homolog (I) was produced. When methanol was substituted for ethanol in the isolation process, only coenzyme Q<sub>10</sub> was isolated.

(1) G. N. Festenstein, F. W. Heaton, J. S. Lowe and R. A. Morton, *Biochem. J.*, **59**, 558 (1955).

(2) R. A. Morton, G. M. Wilson, J. S. Lowe and W. M. F. Leat, *Chem. & Ind.*, 1649 (1957).

(3) R. A. Morton, G. M. Wilson, J. S. Lowe and W. M. F. Leat, *Biochem. J.*, **68**, 16P (1958).

(4) B. O. Linn, A. C. Page, Jr., E. L. Wong, P. H. Gale, C. H. Shunk and K. Folkers, *THIS JOURNAL*, in press.

(4) F. R. Jensen and L. H. Gale, *THIS JOURNAL*, **81**, 1261 (1959).

(5) G. K. Helmkamp, C. D. Joel and H. Sharman, *J. Org. Chem.*, **21**, 844 (1956).

(6) J. Kenyon, H. Phillips and V. P. Pittman, *J. Chem. Soc.*, 1072 (1935).

(7) A. N. Nesmeyanov, O. A. Reutov and S. S. Poddubnaya, *Doklady Akad. Nauk S.S.S.R.*, **88**, 479 (1953).

(8) S. Winstein, T. G. Traylor and C. S. Garner, *THIS JOURNAL*, **77**, 3741 (1955).

The reaction of coenzyme Q<sub>10</sub> with ethanol and sodium ethoxide gave a product, m.p. 34.5–35.5°. *Anal.* Found: C, 82.02; H, 10.44. Its n.m.r. spectrum corresponds to the diethoxy homolog (II).

The name ubiquinone was proposed by Morton, *et al.*,<sup>2,3</sup> "for a substance" which melted at 33–34°, 36°, and 41° ("melting points sharp"). These melting points are significantly lower than that for coenzyme Q<sub>10</sub> (m.p. 48–49°)<sup>5</sup> and correspond closely to those of the diethoxy and the ethoxy homologs. Furthermore, the infrared spectra<sup>1,2</sup> of ubiquinone appear to correspond to the ethoxy derivatives rather than to that of coenzyme Q<sub>10</sub>; spectra of carbon disulfide solutions were compared.

An infrared band at 10.55  $\mu$  for coenzyme Q<sub>10</sub> is absent from the spectrum of the ethoxy product (I), and the latter has new bands at 10.10 and 11.18  $\mu$ . The 8.30, 8.67 and 10.55  $\mu$  bands of coenzyme Q<sub>10</sub> are not in the spectrum of the diethoxy product (II), and the latter exhibits new bands at 8.51, 10.20 and 11.05  $\mu$ . The infrared spectrum<sup>1</sup> of the "best fraction" of ubiquinone (SA) appears identical to that of the diethoxy homolog (II). The infrared spectrum<sup>1</sup> for a second component of ubiquinone (SA) shows bands at 10.20 and 11.1  $\mu$  and no band at 10.55  $\mu$ ; this spectrum is different from that of coenzyme Q<sub>10</sub> and closely resembles that of the ethoxy homolog (I). Morton and co-workers<sup>1</sup> in their isolation of these ubiquinone preparations used hot ethanolic alkali for the saponification of tissues.

The first published description of a crystalline quinone melting at 48–49° was by Crane, *et al.*,<sup>5</sup> in 1957; it was later designated as coenzyme Q<sub>10</sub>.<sup>6</sup> In 1958, Morton and co-workers<sup>7,8</sup> and Bouman, *et al.*,<sup>9</sup> described the same quinone. These investigators have now used the expression ubiquinone, not as originally defined,<sup>2,3</sup> but synonymously with coenzyme Q<sub>10</sub>.

(5) F. L. Crane, Y. Hatefi, R. L. Lester and C. Widmer, *Biochim. et Biophys. Acta*, **25**, 220 (1957).

(6) R. L. Lester, F. L. Crane and Y. Hatefi, *THIS JOURNAL*, **80**, 4751 (1958).

(7) N. I. Fahmy, F. W. Hemming, R. A. Morton, J. Y. F. Paterson, and J. F. Pennock, *Biochem. J.*, **70**, 1P (1958).

(8) R. A. Morton, U. Gloor, O. Schindler, G. M. Wilson, L. H. Chopard-dit-Jean, F. W. Hemming, O. Isler, W. M. F. Leat, J. F. Pennock, R. Rugg, U. Schwieter and O. Wiss., *Helv. Chim. Acta*, **41**, 2343 (1958).

(9) J. Bouman, E. C. Slater, H. Rudney, and J. Links, *Biochim. et Biophys. Acta*, **29**, 456 (1958).

CONTRIBUTION FROM THE  
MERCK SHARP & DOHME  
RESEARCH LABORATORIES  
DIVISION OF MERCK & CO., INC.  
RAHWAY, NEW JERSEY

BRUCE O. LINN  
NELSON R. TRENNER  
CLIFFORD H. SHUNK  
KARL FOLKERS

RECEIVED JANUARY 23, 1959

### STEROIDS. CXVII.<sup>1</sup> 6 $\alpha$ -FLUORO-16 $\alpha$ -HYDROXY CORTICAL HORMONES

Sir:

Among the most recent advances in the cortical hormone field have been the reversal<sup>2</sup> of salt

(1) Paper CXVI, J. A. Edwards, A. Zaffaroni, H. J. Ringold and C. Djerassi, *Proc. Chem. Soc.*, February (1959).

(2) S. Bernstein, R. H. Lenhard, W. S. Allen, M. Heller, R. Littell, S. M. Stolar, L. I. Feldman and R. H. Blank, *THIS JOURNAL*, **78**, 5893 (1956); S. Bernstein, M. Heller, R. Littell, S. M. Stolar, R. H. Lenhard and W. S. Allen, *ibid.*, **79**, 455 (1957).

retention of 9 $\alpha$ -fluoro steroids by 16 $\alpha$ -hydroxylation,<sup>2,3</sup> albeit with somewhat lowered anti-inflammatory activity,<sup>4a,b</sup> the potentiation of activity (with retention of desirable mineral effects) by 16,17-acetonide formation,<sup>4b</sup> and the potentiation of activity by 6 $\alpha$ -fluoro<sup>5a,b</sup> substitution.

We now wish to report the synthesis of a number of representative 6 $\alpha$ -fluoro-16 $\alpha$ -hydroxy cortical hormone analogs in which the combination of several such substituents has been accomplished.

$\Delta^{5,16}$ -Pregnadiene-3 $\beta$ ,21-diol-20-one 21-acetate<sup>6</sup> on successive treatment with potassium permanganate<sup>7</sup> and acetone-perchloric acid gave  $\Delta^5$ -pregnene-3 $\beta$ ,16 $\alpha$ ,17 $\alpha$ ,21-tetrol-20-one 16,17-acetonide 21-acetate (m.p. 215–216.5°,  $[\alpha]_D +8^\circ$ .<sup>8</sup> Found for C<sub>26</sub>H<sub>38</sub>O<sub>6</sub>: C, 70.02; H, 8.58; O, 21.74) and thence by means of monoperphthalic acid the 5 $\alpha$ ,6 $\alpha$ -oxide (m.p. 195–196°,  $[\alpha]_D \pm 0^\circ$ . Found for C<sub>26</sub>H<sub>38</sub>O<sub>7</sub>: C, 67.42; H, 8.16; O, 23.96). Fission with boron trifluoride<sup>9</sup> in ether-benzene yielded the 5 $\alpha$ -hydroxy-6 $\beta$ -fluoro compound (m.p. 224–226°,  $[\alpha]_D +30^\circ$ . Found for C<sub>26</sub>H<sub>39</sub>FO<sub>7</sub>: C, 64.10; H, 8.13; F, 4.11) which was converted to 6 $\alpha$ -fluoro-16 $\alpha$ -hydroxy-"S"-16,17-acetonide-21-acetate (m.p. 295–296°,  $[\alpha]_D +104^\circ$ ,  $\lambda_{max}^{EtOH}$  236 m $\mu$ , log  $\epsilon$  4.19. Found for C<sub>26</sub>H<sub>36</sub>FO<sub>6</sub>: C, 66.74; H, 7.62; F, 4.26) by chromium trioxide oxidation followed by treatment with anhydrous hydrogen chloride in acetone. Cleavage of the acetonide function with 60% formic acid and then saponification gave 6 $\alpha$ -fluoro-16 $\alpha$ -hydroxy-"S" (m.p. 228–230°,  $[\alpha]_D +64^\circ$  (dioxane). Found for C<sub>21</sub>H<sub>29</sub>FO<sub>5</sub>: C, 66.04; H, 7.81) which on incubation with bovine adrenals<sup>10</sup> yielded 6 $\alpha$ -fluoro-16 $\alpha$ -hydroxyhydrocortisone (I) (m.p. 233–235°,  $\lambda_{max}^{EtOH}$  237 m $\mu$ , log  $\epsilon$  4.18. Found for C<sub>21</sub>H<sub>29</sub>FO<sub>6</sub>: C, 63.47; H, 7.42). Alternatively, I was prepared by fermentation of 6 $\alpha$ -fluoro-16 $\alpha$ -hydroxyhydrocortisone<sup>5</sup> with *Streptomyces roseochromogenus*, Rutgers Collection No. 3689.<sup>3</sup> The 16,17-acetonide 21-acetate of I, II (m.p. 261–263°,  $[\alpha]_D +135^\circ$ ,  $\lambda_{max}^{EtOH}$  237 m $\mu$ , log  $\epsilon$  4.18. Found for C<sub>26</sub>H<sub>36</sub>FO<sub>7</sub>: C, 65.08; H, 7.13) furnished on oxidation with selenium dioxide<sup>11</sup> 6 $\alpha$ -fluoro-16 $\alpha$ -hydroxy-prednisolone 16,17-acetonide 21-acetate (III) (m.p. 267–269°  $[\alpha]_D +97^\circ$ ,  $\lambda_{max}^{EtOH}$  241 m $\mu$ , log  $\epsilon$  4.16. Found for C<sub>26</sub>H<sub>33</sub>FO<sub>7</sub>: C, 65.78; H, 7.12). Further, micro-

(3) R. W. Thoma, J. Fried, S. Bonanno and P. Grabowich, *ibid.*, **79**, 4818 (1957).

(4) (a) S. Bernstein, *Rec. Progress in Hormone Res.*, **14**, 1 (1958);

(b) J. Fried, A. Borman, W. B. Kessler, P. Grabowich and E. F. Sabo, *THIS JOURNAL*, **80**, 2338 (1958).

(5) (a) A. Bowers and H. J. Ringold, *ibid.*, **80**, 4423 (1958); (b) J. A. Hogg, G. B. Spero, J. L. Thompson, B. J. Magerlein, W. P. Schneider, D. H. Peterson, O. K. Sebek, H. C. Murray, J. C. Babcock, R. L. Pederson and J. A. Campbell, *Chemistry and Industry*, 1002 (1958).

(6) J. S. Buck and R. O. Clinton, U. S. Patent 2,678,932.

(7) B. Ellis, F. Hartley, V. Petrow and D. Wedlake, *J. Chem. Soc.*, 4383 (1955).

(8) Melting points are uncorrected. Unless stated otherwise rotations were determined in chloroform.

(9) H. B. Henbest and T. I. Wrigley, *J. Chem. Soc.*, 4765 (1957); A. Bowers and H. J. Ringold, *Tetrahedron*, **3**, 14 (1958).

(10) H. Zaffaroni, H. J. Ringold, G. Rosenkranz, F. Sondheimer, G. H. Thomas and C. Djerassi, *THIS JOURNAL*, **80**, 6110 (1958).

(11) H. J. Ringold, G. Rosenkranz and F. Sondheimer, *J. Org. Chem.*, **21**, 239 (1956); C. Meystre, H. Frey, W. Voser and A. Wettstein, *Helv. Chim. Acta*, **39**, 734 (1956); S. A. Szpilfogel, T. A. P. Posthumus, M. S. De Winter and D. A. van Dorp, *Rec. trav. chim.*, **75**, 475 (1956); K. Florey and A. R. Restivo, *J. Org. Chem.*, **22**, 406 (1957).